Marktprognose für Therapeutika gegen Infektionskrankheiten im asiatisch-pazifischen Raum bis 2030 – Regionale Analyse – nach Arzneimittelklasse (antiviral, antibakteriell, antimykotisch und andere), Indikation (HIV, Hepatitis, Tuberkulose, Grippe, HPV und andere), Verabreichungsweg (oral, parenteral, topisch und andere) und Vertriebskanal (Krankenhausapotheken, Einzelhandelsapotheken und andere)
Wachsende Chancen in Entwicklungsländern beflügeln den Markt für Therapeutika gegen Infektionskrankheiten im asiatisch-pazifischen Raum
Die zunehmende Zahl an Infektionskrankheiten wird voraussichtlich den Verkauf von Medikamenten gegen Infektionskrankheiten in Entwicklungsländern steigern. Der asiatisch-pazifische Raum hat sich aufgrund mäßig geringerer Datenanforderungen und strenger Vorschriften zu einem anpassungsfähigen und wirtschaftsfreundlichen Zentrum entwickelt. Darüber hinaus spielen hohe Investitionen in Gesundheitsforschung und Biowissenschaften in Schwellenländern eine Schlüsselrolle bei der Förderung der neuesten Technologien in Entwicklungsländern, was wiederum die Neigung zur Diagnose und Behandlung von Infektionskrankheiten unterstützt. So fordert UNAIDS beispielsweise Investitionen in Höhe von 29 Milliarden US-Dollar bis 2025, um den Bedarf der Länder mit niedrigem und mittlerem Einkommen im Rahmen der AIDS-Bekämpfung zu decken. Daher wird erwartet, dass sich den Herstellern wichtiger Produkte zur Behandlung von Infektionskrankheiten in den aufstrebenden Märkten für Behandlungen von Infektionskrankheiten in Indien und Südkorea in Zukunft lukrative Gelegenheiten bieten. Dies ist auf die hohe Verbreitung von Infektionskrankheiten wie Hepatitis, HAI, HIV und Grippe, eine große Patientenpopulation, einen Anstieg des verfügbaren Einkommens der Bevölkerung, eine verbesserte Gesundheitsinfrastruktur und einen wachsenden Medizintourismus in diesen Ländern zurückzuführen.
Überblick über den Markt für Behandlungen von Infektionskrankheiten im asiatisch-pazifischen Raum
Der Markt für Behandlungen von Infektionskrankheiten im asiatisch-pazifischen Raum ist in China, Indien, Japan, Südkorea, Australien und den Rest des asiatisch-pazifischen Raums unterteilt. Der asiatisch-pazifische Raum wird im Prognosezeitraum voraussichtlich die schnellste durchschnittliche jährliche Wachstumsrate verzeichnen. Der Markt in der Region wird voraussichtlich aufgrund steigender globaler Gesundheitsausgaben, der zunehmenden Häufigkeit chronischer und infektiöser Krankheiten und einer wachsenden geriatrischen Bevölkerungsbasis wachsen. Infektionskrankheiten wie Grippe, Hepatitis B und infektiöse Durchfallerkrankungen sind in China weit verbreitet und Typhus, Malaria, Gelbsucht, Tuberkulose und AIDS in Indien. Grippe, Hepatitis B und infektiöse Durchfallerkrankungen sind die drei häufigsten Infektionskrankheiten in China. Wie Frontiers Public Health angibt, fiel der Winterhöhepunkt der Grippe mit dem Ausbruch von COVID-19 im Land im Jahr 2021 zusammen. Laut dem Länderdirektor der Weltbank für China 2020 ist das Land aufgrund seiner wachsenden Bevölkerung, seines Wildtierreichtums, seiner Lebensraumfragmentierung und seiner hohen Viehproduktion einem hohen Risiko von Infektionskrankheiten ausgesetzt. Angesichts der zunehmenden Zahl von Infektionskrankheiten im Land genehmigte der Vorstand der Weltbank ein Darlehen in Höhe von 300 Millionen US-Dollar für das Projekt zur Prävention, Vorbereitung und Reaktion auf neu auftretende Infektionskrankheiten. Dies wird dazu beitragen, das Risiko von Zoonosen und anderen neu auftretenden Gesundheitsbedrohungen zu verringern. Daher wird erwartet, dass die steigende Zahl von Infektionskrankheiten und die Maßnahmen zu ihrer Eindämmung den chinesischen Markt für Therapeutika für Infektionskrankheiten in den kommenden Jahren ankurbeln werden.
Marktumsatz und Prognose für Therapeutika für Infektionskrankheiten im asiatisch-pazifischen Raum bis 2030 (in Mio. USD)
Marktsegmentierung für Therapeutika für Infektionskrankheiten im asiatisch-pazifischen Raum
Der Markt für Therapeutika für Infektionskrankheiten im asiatisch-pazifischen Raum ist nach Arzneimittelklasse, Indikation, Verabreichungsweg, Vertriebskanal und Land kategorisiert.
Basierend auf der Arzneimittelklasse ist der Markt für Therapeutika für Infektionskrankheiten im asiatisch-pazifischen Raum in antivirale, antibakterielle, antimykotische und andere Mittel unterteilt. Das antivirale Segment hatte 2022 den größten Marktanteil.
In Bezug auf die Indikation ist der Markt für Therapeutika für Infektionskrankheiten im asiatisch-pazifischen Raum in HIV, Hepatitis, Tuberkulose, Influenza, HPV und andere unterteilt. HIV hatte 2022 den größten Marktanteil.
Basierend auf dem Verabreichungsweg ist der Markt für Therapeutika für Infektionskrankheiten im asiatisch-pazifischen Raum in oral, parenteral, topisch und andere unterteilt. Das orale Segment hatte 2022 den größten Marktanteil.
In Bezug auf die Vertriebskanäle ist der Markt für Therapeutika für Infektionskrankheiten im asiatisch-pazifischen Raum in Krankenhausapotheken, Einzelhandelsapotheken und andere unterteilt. Die Krankenhausapotheken hatten 2022 den größten Marktanteil.
Nach Ländern ist der Markt für Therapeutika für Infektionskrankheiten im asiatisch-pazifischen Raum in China, Japan, Indien, Australien, Südkorea und den Rest des asiatisch-pazifischen Raums unterteilt. China dominierte 2022 den Marktanteil für Therapeutika für Infektionskrankheiten im asiatisch-pazifischen Raum.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, Pfizer Inc und Shionogi & Co Ltd sind einige der führenden Unternehmen auf dem Markt für Therapeutika für Infektionskrankheiten im asiatisch-pazifischen Raum.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Growing Opportunities in Developing Nations
4.4.2 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - Asia Pacific Market Analysis
5.1 Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Infectious Disease Therapeutics Market - Country Analysis
10.1 Asia Pacific Infectious Disease Therapeutics Market Overview
10.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.3 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 China: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 China: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.3.3 China: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.4 China: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.4 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.5 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Japan: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.5.2 Japan: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.5.3 Japan: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.5.4 Japan: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.6 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.7 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 India: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.7.2 India: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.7.3 India: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
10.1.1.7.4 India: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.8 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.8.1 Overview
10.1.1.9 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.9.1 Australia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.9.2 Australia: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.9.3 Australia: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
10.1.1.9.4 Australia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.10 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.10.1 Overview
10.1.1.11 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.11.1 South Korea: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.11.2 South Korea: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.11.3 South Korea: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.11.4 South Korea: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.12 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.12.1 Overview
10.1.1.13 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.13.1 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.13.2 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.13.3 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.13.4 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Shionogi & Co Ltd
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bayer AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 GSK Plc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 AbbVie Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Merck & Co Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Astellas Pharma Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation
Table 2. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 3. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 4. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 5. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 6. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
Table 7. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 8. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 9. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 10. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 11. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 12. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 13. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 14. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 15. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 16. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 17. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
Table 18. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 19. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 20. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 21. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
Table 22. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 23. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 24. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 25. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 26. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 27. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 28. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 29. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 30. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
List of Figures
Figure 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Asia Pacific Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. F. Hoffmann-La Roche Ltd
5. Gilead Sciences Inc
6. GSK Plc
7. Merck & Co Inc
8. Pfizer Inc
9. Shionogi & Co Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific infectious disease therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific infectious disease therapeutics market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.